Skip to main content
Erschienen in: Journal of Cancer Survivorship 4/2017

13.02.2017 | Review

Life beyond a diagnosis of glioblastoma: a systematic review of the literature

verfasst von: L Gately, SA McLachlan, A Dowling, J Philip

Erschienen in: Journal of Cancer Survivorship | Ausgabe 4/2017

Einloggen, um Zugang zu erhalten

Abstract

Background

The median survival of glioblastoma is 12–14 months with less than 10% of patients surviving at least 2 years from diagnosis. Patients diagnosed with glioblastoma face poor prognosis, significant symptom burden, and high care needs. The aim of this study is to undertake a literature review to document the issues encountered by long-term survivors of glioblastoma, a small but important subset of patients.

Methods

MEDLINE, PsychInfo, and EMBASE were searched with core concepts: (1) glioblastoma, (2) survivor, and (3) terms pertaining to survivorship issues. A thematic analysis was undertaken of the three included studies.

Results

Long-term survivors of glioblastoma encounter neurologic deficits, impairment in cognition, psychological distress, reduced social function, and future uncertainty. These issues result in the inability to return to work and financial difficulties. Independence in activities of daily living, working memory, and overall quality of life appears to be preserved.

Conclusions

Long-term survivors of glioblastoma continue to have significant symptom burden and care needs. There is currently a paucity of literature surrounding this topic. Further research is required to accurately describe these issues in order for improved supportive care to be implemented in the community and the outpatient setting.

Implications for Cancer Survivors

Understanding the issues faced by long-term survivor of glioblastoma will provide insight into the care needs of patients as well as support networks required for patients and their carers.
Literatur
1.
Zurück zum Zitat Dobes M, Khurana V, Shadbolt B, et al. Increasing incidence of glioblastoma multiforme and meningioma, and decreasing incidence of schwannoma (2000-2008): findings of a multicentre Australian study. Surg Neurol Int. 2011;2:176.CrossRefPubMedPubMedCentral Dobes M, Khurana V, Shadbolt B, et al. Increasing incidence of glioblastoma multiforme and meningioma, and decreasing incidence of schwannoma (2000-2008): findings of a multicentre Australian study. Surg Neurol Int. 2011;2:176.CrossRefPubMedPubMedCentral
2.
Zurück zum Zitat Stupp R, Hegi ME, Mason WP, et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomized phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol. 2009;10(5):459–66.CrossRefPubMed Stupp R, Hegi ME, Mason WP, et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomized phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol. 2009;10(5):459–66.CrossRefPubMed
3.
Zurück zum Zitat Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005;352(10):987–96.CrossRefPubMed Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005;352(10):987–96.CrossRefPubMed
4.
Zurück zum Zitat Schmidinger M, Linzmayer L, Becherer A, et al. Psychometric- and quality-of-life assessment in long-term glioblastoma survivors. J Neuro-Oncol. 2003;63(1):55–61.CrossRef Schmidinger M, Linzmayer L, Becherer A, et al. Psychometric- and quality-of-life assessment in long-term glioblastoma survivors. J Neuro-Oncol. 2003;63(1):55–61.CrossRef
5.
Zurück zum Zitat Steinbach JP, Blaicher HP, Herrlinger U, et al. Surviving glioblastoma for more than 5 years: the patient’s perspective. Neurology. 2006;66:239–42.CrossRefPubMed Steinbach JP, Blaicher HP, Herrlinger U, et al. Surviving glioblastoma for more than 5 years: the patient’s perspective. Neurology. 2006;66:239–42.CrossRefPubMed
6.
Zurück zum Zitat Ostrom QT, Gittleman H, Farah P, et al. CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2006-2010. Neuro-Oncology. 2013;15(Suppl 2):ii1–ii56.CrossRefPubMedPubMedCentral Ostrom QT, Gittleman H, Farah P, et al. CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2006-2010. Neuro-Oncology. 2013;15(Suppl 2):ii1–ii56.CrossRefPubMedPubMedCentral
7.
Zurück zum Zitat Krex D, Klink B, Hartmann C et al. Long-term survival with glioblastoma multiforme. First published online: 4 September 2007;2596–2606. doi:10.1093/brain/awm204. Krex D, Klink B, Hartmann C et al. Long-term survival with glioblastoma multiforme. First published online: 4 September 2007;2596–2606. doi:10.​1093/​brain/​awm204.
8.
Zurück zum Zitat Sacko A, Hou MM, Temgoua M, et al. Evolution of the Karnosky Performance Status throughout life in glioblastoma patients. J Neuro-Oncol. 2015;122(3):567–73.CrossRef Sacko A, Hou MM, Temgoua M, et al. Evolution of the Karnosky Performance Status throughout life in glioblastoma patients. J Neuro-Oncol. 2015;122(3):567–73.CrossRef
9.
Zurück zum Zitat Giovagnoli AR, Silvani A, Colombo E, et al. Facets and determinants of quality of life in patients with recurrent high grade glioma. J Neurol Neurosurg Psychiatry. 2005;76:562–8.CrossRefPubMedPubMedCentral Giovagnoli AR, Silvani A, Colombo E, et al. Facets and determinants of quality of life in patients with recurrent high grade glioma. J Neurol Neurosurg Psychiatry. 2005;76:562–8.CrossRefPubMedPubMedCentral
10.
Zurück zum Zitat Meyers C, Boake C. Neurobehavioral disorders experienced by brain tumor patients: rehabilitation strategies. Cancer Bull. 1993;45:362–4. Meyers C, Boake C. Neurobehavioral disorders experienced by brain tumor patients: rehabilitation strategies. Cancer Bull. 1993;45:362–4.
11.
Zurück zum Zitat Sizoo E, Dirven L, Reijneveld J, et al. Measuring health-related quality of life in high-grade glioma patients at the end of life using a proxy-reported retrospective questionnaire. J Neuroonc. 2014;116(2):283–90.CrossRef Sizoo E, Dirven L, Reijneveld J, et al. Measuring health-related quality of life in high-grade glioma patients at the end of life using a proxy-reported retrospective questionnaire. J Neuroonc. 2014;116(2):283–90.CrossRef
12.
Zurück zum Zitat Smoll NR, Schaller K, Gautschi OP. Long-term survival of patients with glioblastoma multiforme (GBM). J Clin Neurosci. 2013;20(5):670–5.CrossRefPubMed Smoll NR, Schaller K, Gautschi OP. Long-term survival of patients with glioblastoma multiforme (GBM). J Clin Neurosci. 2013;20(5):670–5.CrossRefPubMed
13.
Zurück zum Zitat Hottinger A, Yoon H, DeAngelis L, et al. Neurological outcome of long-term glioblastoma survivors. J Neuro-Oncol. 2009;95:301–5.CrossRef Hottinger A, Yoon H, DeAngelis L, et al. Neurological outcome of long-term glioblastoma survivors. J Neuro-Oncol. 2009;95:301–5.CrossRef
14.
Zurück zum Zitat Flechl B, Ackerl M, Sax C, et al. Neurocognitive and sociodemographic functioning of glioblastoma long-term survivors. J Neuro-Oncol. 2012;109:331–9.CrossRef Flechl B, Ackerl M, Sax C, et al. Neurocognitive and sociodemographic functioning of glioblastoma long-term survivors. J Neuro-Oncol. 2012;109:331–9.CrossRef
16.
Zurück zum Zitat Douw L, Klein M, Fagel SS, et al. Cognitive and radiological effects of radiotherapy in patients with low-grade glioma: long-term follow-up. Lancet Neurol. 2009;8(9):810–8.CrossRefPubMed Douw L, Klein M, Fagel SS, et al. Cognitive and radiological effects of radiotherapy in patients with low-grade glioma: long-term follow-up. Lancet Neurol. 2009;8(9):810–8.CrossRefPubMed
17.
Zurück zum Zitat Ford E, Catt S, Chalmers A, et al. Systematic review of supportive care needs in patients with primary malignant brain tumors. Neuro-Oncology. 2012;14(4):392–404.CrossRefPubMedPubMedCentral Ford E, Catt S, Chalmers A, et al. Systematic review of supportive care needs in patients with primary malignant brain tumors. Neuro-Oncology. 2012;14(4):392–404.CrossRefPubMedPubMedCentral
18.
Zurück zum Zitat Boele FW, Douw L, Reijneveld JC, et al. Health-related quality of life in stable, long-term survivors of low-grade glioma. JCO. 2015;33(9):1023–9.CrossRef Boele FW, Douw L, Reijneveld JC, et al. Health-related quality of life in stable, long-term survivors of low-grade glioma. JCO. 2015;33(9):1023–9.CrossRef
19.
Zurück zum Zitat Kiebert GM, Curran D, Aaronson NK, et al. Quality of life after radiation therapy of cerebral low-grade gliomas of the adult: results of a randomized phase III trial on dose response (EORTC trial 22844). EORTC Radiotherapy Co-operative Group. Eur J Cancer. 1998;34(12):1902–9.CrossRefPubMed Kiebert GM, Curran D, Aaronson NK, et al. Quality of life after radiation therapy of cerebral low-grade gliomas of the adult: results of a randomized phase III trial on dose response (EORTC trial 22844). EORTC Radiotherapy Co-operative Group. Eur J Cancer. 1998;34(12):1902–9.CrossRefPubMed
Metadaten
Titel
Life beyond a diagnosis of glioblastoma: a systematic review of the literature
verfasst von
L Gately
SA McLachlan
A Dowling
J Philip
Publikationsdatum
13.02.2017
Verlag
Springer US
Erschienen in
Journal of Cancer Survivorship / Ausgabe 4/2017
Print ISSN: 1932-2259
Elektronische ISSN: 1932-2267
DOI
https://doi.org/10.1007/s11764-017-0602-7

Weitere Artikel der Ausgabe 4/2017

Journal of Cancer Survivorship 4/2017 Zur Ausgabe

Alter verschlechtert Prognose bei Endometriumkarzinom

11.05.2024 Endometriumkarzinom Nachrichten

Ein höheres Alter bei der Diagnose eines Endometriumkarzinoms ist mit aggressiveren Tumorcharakteristika assoziiert, scheint aber auch unabhängig von bekannten Risikofaktoren die Prognose der Erkrankung zu verschlimmern.

Darf man die Behandlung eines Neonazis ablehnen?

08.05.2024 Gesellschaft Nachrichten

In einer Leseranfrage in der Zeitschrift Journal of the American Academy of Dermatology möchte ein anonymer Dermatologe bzw. eine anonyme Dermatologin wissen, ob er oder sie einen Patienten behandeln muss, der eine rassistische Tätowierung trägt.

Erhöhte Mortalität bei postpartalem Brustkrebs

07.05.2024 Mammakarzinom Nachrichten

Auch für Trägerinnen von BRCA-Varianten gilt: Erkranken sie fünf bis zehn Jahre nach der letzten Schwangerschaft an Brustkrebs, ist das Sterberisiko besonders hoch.

Hypertherme Chemotherapie bietet Chance auf Blasenerhalt

07.05.2024 Harnblasenkarzinom Nachrichten

Eine hypertherme intravesikale Chemotherapie mit Mitomycin kann für Patienten mit hochriskantem nicht muskelinvasivem Blasenkrebs eine Alternative zur radikalen Zystektomie darstellen. Kölner Urologen berichten über ihre Erfahrungen.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.